HOLX - Hologic, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.29
+1.06 (+2.34%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close45.23
Open45.53
Bid42.92 x 1200
Ask46.57 x 800
Day's Range45.33 - 46.31
52 Week Range35.10 - 46.32
Volume2,001,084
Avg. Volume2,424,673
Market Cap13.485B
Beta (3Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)-1.53
Earnings DateApr 30, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.31
Trade prices are not sourced from all markets
  • Hologic’s Aptima HIV-1 Quant Dx Assay Receives Two CE Marks, Making It the First and Only Dual-Claim Assay for Both Viral Load and Early Infant Diagnosis
    Business Wire5 days ago

    Hologic’s Aptima HIV-1 Quant Dx Assay Receives Two CE Marks, Making It the First and Only Dual-Claim Assay for Both Viral Load and Early Infant Diagnosis

    Hologic, Inc. (HOLX) announced today that its Aptima® HIV-1 Quant Dx Assay has received two new CE marks in Europe – for early infant diagnosis (EID) and for testing dried blood spots (DBS). This means the assay can be used to qualitatively detect HIV-1 RNA as an aid in the diagnosis of HIV-1 infected infants under 18 months old, and to test an additional sample type (DBS) to monitor viral load and disease progression in HIV-1 infected individuals in European and African countries. It is the first and only dual-claim assay for both viral load and early infant diagnosis.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Hologic Inc.

    Hologic Inc NASDAQ/NGS:HOLXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for HOLX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $17.17 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Bright Near-Term Outlook for Medical Instruments Industry
    Zacks11 days ago

    Bright Near-Term Outlook for Medical Instruments Industry

    Bright Near-Term Outlook for Medical Instruments Industry

  • Here's Why Momentum Investors Will Love Hologic (HOLX)
    Zacks14 days ago

    Here's Why Momentum Investors Will Love Hologic (HOLX)

    Does Hologic (HOLX) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Thomson Reuters StreetEvents18 days ago

    Edited Transcript of HOLX earnings conference call or presentation 30-Jan-19 9:30pm GMT

    Q1 2019 Hologic Inc Earnings Call

  • Hologic's (HOLX) Q1 Earnings Beat Estimates, Guidance Raised
    Zacks18 days ago

    Hologic's (HOLX) Q1 Earnings Beat Estimates, Guidance Raised

    Hologic (HOLX) gains from solid double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics.

  • Benzinga18 days ago

    The Daily Biotech Pulse: Hologic, Celgene Earnings, FDA To Rule On Alkermes Depression Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 30) Varian Medical Systems, Inc. (NYSE: VAR ) EXACT Sciences ...

  • Hologic Inc (HOLX) Q1 2019 Earnings Conference Call Transcript
    Motley Fool19 days ago

    Hologic Inc (HOLX) Q1 2019 Earnings Conference Call Transcript

    HOLX earnings call for the period ending December 29, 2018.

  • Hologic (HOLX) Q1 Earnings and Revenues Beat Estimates
    Zacks19 days ago

    Hologic (HOLX) Q1 Earnings and Revenues Beat Estimates

    Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.51%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press19 days ago

    Hologic: Fiscal 1Q Earnings Snapshot

    MARLBOROUGH, Mass. (AP) _ Hologic Inc. (HOLX) on Wednesday reported fiscal first-quarter net income of $98.6 million. The Marlborough, Massachusetts-based company said it had profit of 36 cents per share. For the current quarter ending in April, Hologic expects its per-share earnings to range from 55 cents to 57 cents.

  • Business Wire19 days ago

    Hologic Announces Financial Results for First Quarter of Fiscal 2019

    – Revenue of $830.7 Million Grows 5.0%, 5.7% in Constant Currency –

  • What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?
    Zacks25 days ago

    What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?

    Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.

  • New Hologic Assay is First and Only FDA-Cleared Diagnostic Test to Detect Emerging Health Threat Mycoplasma genitalium
    Business Wire26 days ago

    New Hologic Assay is First and Only FDA-Cleared Diagnostic Test to Detect Emerging Health Threat Mycoplasma genitalium

    -- FDA clearance makes clinically validated assay available for sexually-transmitted infection listed as emerging threat by the CDC --

  • CNBC26 days ago

    These stocks historically jump the most during the first earnings season of the year

    Companies that repeatedly see their stocks jump after earnings could do so again, so Bespoke created a list of stocks that popped the most on the last eight years of fourth-quarter earnings reporting days.

  • Hologic (HOLX) Earnings Expected to Grow: Should You Buy?
    Zacks26 days ago

    Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

    Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswirelast month

    Market Trends Toward New Normal in Altria Group, Anthem, SemGroup, Axcelis Technologies, M.D.C., and Hologic — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Hologic, Inc.’s (NASDAQ:HOLX) Investment Returns Are Lagging Its Industry
    Simply Wall St.last month

    Hologic, Inc.’s (NASDAQ:HOLX) Investment Returns Are Lagging Its Industry

    Today we'll evaluate Hologic, Inc. (NASDAQ:HOLX) to determine whether it could have potential as an investment idea. Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give Read More...

  • 3 Big Stock Charts for Friday: General Electric, Hologic and MGM Resorts
    InvestorPlacelast month

    3 Big Stock Charts for Friday: General Electric, Hologic and MGM Resorts

    It wasn't a screaming victory, but Thursday's 0.45% gain for the S&P 500 marks its fifth gain in a row. Observers are gaining confidence, though shrinking volume says actual participants are thinning out. Bed Bath & Beyond (NASDAQ:BBBY) led the way with its 16.6% romp in response to an unexpectedly strong 2019 outlook. Twitter (NYSE:TWTR) made some bullish waves as well, however, up a healthy 2.6% after Bank of America's Merrill Lynch upgraded TWTR stock from "underperform" to "buy," citing an opportunity to improve user engagement. There weren't a whole lot more advancers than decliners though, with Target Corporation (NYSE:TGT) doing the most collective damage. Shares of the big-box store were off 2.9% in sympathy with a couple of alarming reports from rival retailers. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the marketwide rally is anything but sweeping, that's beneficial in the sense that winners are separated from losers and actual trends can develop without the market's interference. To that end, stock charts of General Electric (NYSE:GE), Hologic (NASDAQ:HOLX) and MGM Resorts International (NYSE:MGM) are among the best of those bets heading into the weekend. ### Hologic (HOLX) More than once in recent months Hologic has merited a closer look. The converging trading range has been building up some pent-up action. It just needed the right catalyst to put that move into motion … higher or lower. * Morgan Stanley: 7 Risky Stocks to Sell Now It looked like that was going to happen in November, in a bullish direction, but the broad market tide had other plans for HOLX. Thursday's break back above the long-term technical ceiling, however, may be the one that sticks now that the market is helping. Click to Enlarge • The converging trading range in question is plotted by white dashed lines on both stock charts. Hologic is back above the upper edge of that range as of yesterday's close. • Still, given the fake-out seen a few weeks ago, the smart-money move here may be waiting to see if HOLX can push back above the technical ceiling around $45, plotted with a yellow dashed line. • While the undertow has actually been bullish for several weeks, any move between here and $45 is unlikely to be a straight line. It still may be worth the wait, however. ### General Electric (GE) Though well up from its late-December low, the gain General Electric shares have dished out since then has been in question. The doubters were feeling particularly vindicated on Tuesday and Wednesday, when the advance stopped and reversed. Looking back on Wednesday's and Thursday's bars, however, the bullish case for GE may be even better now specifically because of the stumble. Click to Enlarge • Wednesday's bar, marked with a yellow arrow, only had to kiss the recently hurdled 50-day moving average line, plotted in purple, to renew the buying effort. Thursday's follow-through confirms Wednesday's doji was indeed a pivot. • The previous line in the sand is still in play, however. That's the $9 area, where General Electric has found a ceiling more than once in recent weeks. • Looking back, the November meltdown looks like it could have been a capitulation of sorts. We've seen more buying volume for GE now than we have in months. ### MGM Resorts International (MGM) Finally, three weeks ago, MGM Resorts International looked like it was in massive trouble. As of two weeks ago, that idea was in question. One week ago, MGM looked ready to take flight. As of this morning, nobody has a clue. Thursday's action raised far more questions than answers. The good news is, the bulls and the bears are going to have to make a decision soon. The lines in the sand are pretty clear too. Click to Enlarge • The shape of yesterday's bar is telling. The bulls were content to pile on early on, but by the end of the day most of the bulls were getting back out again. This looks like the pivot out of the uptrend. • Or, maybe it isn't. The buying volume this week has not only been above average, it has been growing too. On the weekly chart we've got a fresh MACD buy signal and a Chaikin line back above zero. • A pause here isn't surprising, as the white 200-day moving average line comes into view. From here, the bulls will have to either take MGM to the next level or throw in the towel. If the 200-day line can be hurdled, that should be a bullish catalyst. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 3 Big Stock Charts for Friday: General Electric, Hologic and MGM Resorts appeared first on InvestorPlace.

  • Hologic Stock Rides on Impressive Preliminary Q1 Result
    Zackslast month

    Hologic Stock Rides on Impressive Preliminary Q1 Result

    Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.

  • Business Wirelast month

    Hologic to Announce Financial Results for the First Quarter of Fiscal 2019 on Wednesday, January 30, 2019

    Hologic, Inc. announced today that the Company plans to release its financial results for the first quarter of fiscal 2019 on Wednesday, January 30, 2019, after the market closes.

  • MarketWatchlast month

    Hologic's stock surges after revenue outlook beats expectations

    Shares of Hologic Inc. ran up 4.7% in premarket trade Monday, after the medical technology company provided a fiscal first-quarter revenue outlook that was above expectations. The company said it expects revenue for the quarter ended Dec. 29 of $831 million, up 55 from a year ago, and above the FactSet consensus of $812 million. Among its largest business segments, the company expects breast health revenue to rise to $325 million from $288 million, above the FactSet consensus of $305 million, and expects diagnostics revenue to grow to $297 million from $285 million, better than expectations of $290 million. The company is expected to report full results in early February. The stock has slipped 3.3% over the past three months, while the SPDR Health Care Select Sector ETF has lost 8.8% and the S&P 500 has declined 12.3%.